{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dickert NW"],"funding":["AHRQ HHS"],"pagination":["e011273"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11745761"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["<h4>Background</h4>Guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction can entail high out-of-pocket (OOP) costs, prompting concerns about financial toxicity and access. OOP costs are generally unavailable during encounters. This trial assessed the impact of providing patient-specific OOP costs to patients and clinicians.<h4>Methods</h4>This trial was conducted between June 2021 and August 2023 at 6 clinics in 2 health systems using a stepped-wedge, clinic-level cluster-randomized design. Adult patients with HF with reduced ejection fraction (left ventricular ejection fraction ≤40%) were enrolled. The intervention was built upon the EPIC-HF (Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure wi"],"journal":["Circulation. Cardiovascular quality and outcomes"],"pubmed_title":["Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF)."],"pmcid":["PMC11745761"],"funding_grant_id":["R01 HS026081"],"pubmed_authors":["Scherer LD","Rao BR","Matlock DD","Sloan CE","Halpern SD","Mitchell AR","Montembeau SC","Noonan K","Ubel PA","Allen LA","Ko YA","Morris AA","Dickert NW","Speight CD","Biermann H","Moore MA","Balser M","Davis JK","Krishnan A"],"additional_accession":[]},"is_claimable":false,"name":"Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).","description":"<h4>Background</h4>Guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction can entail high out-of-pocket (OOP) costs, prompting concerns about financial toxicity and access. OOP costs are generally unavailable during encounters. This trial assessed the impact of providing patient-specific OOP costs to patients and clinicians.<h4>Methods</h4>This trial was conducted between June 2021 and August 2023 at 6 clinics in 2 health systems using a stepped-wedge, clinic-level cluster-randomized design. Adult patients with HF with reduced ejection fraction (left ventricular ejection fraction ≤40%) were enrolled. The intervention was built upon the EPIC-HF (Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure wi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-07-15T11:05:19.29Z","creation":"2025-04-05T09:32:41.713Z"},"accession":"S-EPMC11745761","cross_references":{"pubmed":["39624892"],"doi":["10.1161/circoutcomes.124.011273","10.1161/CIRCOUTCOMES.124.011273"]}}